The launch of the fund follows Sanofi’s investment in a $1bn insulin production facility in Beijing, China.
French pharmaceutical and healthcare firm Sanofi has partnered with investment firm Cathay Capital to launch a $275m fund that will invest in clinical-stage drugs in China.
The new fund, first reported by DealStreetAsia, was announced during a ceremony in Sanofi’s Shanghai office earlier this week.
The Sanofi-Cathay Pharmaceutical Innovation Fund will invest in Chinese pharmaceutical companies to help them transition from drug R&D to commercialisation and accelerate their access to global markets.
The fund is a continuation of Sanofi and Cathay Capital’s existing partnership, which started with Sanofi’s investment in Cathay in 2020, aimed at strengthening its connection to healthcare markets, particularly in China.
Sanofi plans to invest about $1.1bn in a new insulin production base in Beijing, marking its biggest single investment in the country.
Sanofi, which has been operating in China since 1982, has 12 offices in the country, three production facilities and four R&D centres.
